An observational study in Risk Factors, Polypharmacy and Drug Interactions, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences · Observational
The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics will be assessed. The continuous depersonalized online survey is performed using the original informational resources in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation.
Polypharmacy-associated serious drug-drug interactions and adverse drug reactions may increase the risk of morbidity and mortality in the population, especially in cardiovascular patients. Insufficient patient compliance to treatment and potential self-medication overlap with behavioral, psychosocial, demographic, and environmental conditions and pose new challenges for the population striving to achieve active longevity. These issues have been especially relevant during and after the COVID-19 pandemic. The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. Telecommunication approaches are used for the formation of study cohort. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics of study cohort will be assessed. The continuous depersonalized online survey is performed using the original informational resource in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The acquired data may lay a foundation for the development decision support system for control of previously unrecognized or poorly recognized risk factors. The study will enroll as least 2000 respondents aged 18 years and older. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation. Both websites have built-in functionality for downloading survey results in tabular format (.xls, .csv). All the respondents are required to sign the informed consent form electronically according to local legislation and international standards of ethical research. Considering that no physical medical examinations or interventions are involved in the study, and all data undergo complete depersonalization, participation in this study does not pose any risks for respondents. Financial support for the study is provided by the Russian Science Foundation (project No. 22-15-00313). Respondents will not be covered by insurance due to the non-interventional nature of the study.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Tomsk National Research Medical Center of the Russian Academy of Sciences is the lead sponsor of 73 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Nonstructured population aged 18 years and older willing to complete the entire questionnaire and signing the informed concent form.
Exclusion Criteria:
The respondent will represent the non-structured population of the Russian Federation invited to participate in the study using the SMS-Target tool provided by OOO T2 Mobile Company.
Other: Online Survey · Diagnostic Test: Genetic Testing
The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
Also known as: Telecommunication-Based Survey
Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
Also known as: Genetic Polymorphisms of Drug-Metabolizing Enzymes
Incidence of serious drug-drug interactions (percent)
Incidence of serious drug-drug interactions (DDIs) is assessed as a percentage (%) of completed survey questionnaires associated with serious DDIs relative to the size of respondent population.
Time frame: Five years
Median number of serious drug-drug interactions (n)
Median number of serious drug-drug interactions is assessed per one completed survey questionnaire containing information on pharmacotherapy.
Time frame: Five years
Incidence of polypharmacy (percent)
Polypharmacy refers to using five or more medications. Incidence of polypharmacy is assessed as a percentage (%) of completed survey questionnaires reporting polypharmacy relative to the size of respondent population.
Time frame: Five years
Incidence of MRI administration (percent)
Incidence of magnetic resonance tomography (MRI) administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing MRI procedure for the past two years relative to the size of respondent population.
Time frame: Two years
Incidence of CT administration (percent)
Incidence of computed tomography (CT) administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing CT procedure for the past two years relative to the size of respondent population.
Time frame: Two years
Incidence of diagnostic ultrasound administration (percent)
Incidence of diagnostic ultrasound administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing ultrasonography procedure for the past two years relative to the size of respondent population.
Time frame: Two years
Incidence of diagnostic X-ray administration (percent)
Incidence of diagnostic X-ray administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing X-ray for the past two years relative to the size of respondent population.
Time frame: Two years
Incidence of scintigraphy administration (percent)
Incidence of scintigraphy administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing scintigraphy for the past two years relative to the size of respondent population.
Time frame: Two years
Incidence of chest fluoroscopy administration (percent)
Incidence of chest fluoroscopy administration is assessed as a percentage (%) of completed survey questionnaires where respondents report the fact of undergoing chest fluoroscopy for the past two years relative to the size of respondent population.
Time frame: Two years
Clinically significant CYP2D6 gene polymorphisms
Clinically significant CYP2D6 gene polymorphisms will be identified by diagnostic sequencing using EDTA whole blood.
Time frame: Two months
Clinically significant ACE gene polymorphisms
Clinically significant ACE gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.
Time frame: Two months
Clinically significant UGT1A1 gene polymorphisms
Clinically significant UGT1A1 gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.
Time frame: Two months
Clinically significant CYP2C9 gene polymorphisms
Clinically significant CYP2C9 gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.
Time frame: Two months
Clinically significant CYP2C19 gene polymorphisms
Clinically significant CYP2C19 gene polymorphisms will be identified by real-time PCR with melting curve detection using EDTA whole blood.
Time frame: Two months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tomsk National Research Medical Center of the Russian Academy of Sciences